Julian Burke appointed chair of Camena Bioscience’s board
Cambridge, UK: Camena Bioscience, a leading DNA synthesis company, today announced that Julian Burke has become chair of the board.
“We are very excited to welcome Julian to the board and honoured that he will be our Chair”, said Camena Bioscience CEO, Steve Harvey. “Julian is a highly experienced life science executive and his appointment further strengthens our governance”.
Julian Burke added, “Camena Bioscience has made a tremendous advancement in gene synthesis technology, which is critical for all major areas of industrial and academic R&D. It’s exciting to join to team as they enter a growth phase and the commercialisation of their gene synthesis technology”.
Julian is an experienced executive and has held several influential roles within life science businesses. Previously he was the Chief Scientist and VP of New Ventures at Danaher, CSO of Leica Microsystems and CSO of Molecular Devices. He was the CEO and founder of Genpak, a company that provided reagents and robotics for DNA sequencing, which was acquired by Genetix. Following the acquisition, Julian was the CSO of Genetix and helped the company to complete a successful IPO in 2000. Additionally, he is a visiting professor at Southampton University and holds over 100 publications and 10 patents.
About Camena Bioscience
Camena Bioscience is the developer of pioneering technology aimed at enabling the rapidly expanding synthetic biology field. gSynth™, Camena Bioscience’s multi-enzymatic de novo synthesis and gene assembly method, offers increased accuracy over existing DNA synthesis technologies. Camena Bioscience has offices in Cambridge (UK) and California.